Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy
BMJ Supportive & Palliative Care November 3, 2025 Yvan Beaussant, Zachary Sager, Caitlin W. Brennan et al. 1 citation
A single 25 mg dose of psilocybin, combined with preparation and integration sessions, was safely administered to ten terminally ill home hospice patients. No serious adverse events occurred. Demoralization scores dropped by an average of 8.8 points three weeks after the session, despite patients' ongoing physical decline. Grief and peace themes were common during the drug sessions. Although most participants rated the treatment favorably, some found the emotional intensity challenging. The results suggest that psilocybin-assisted therapy can be feasibly and safely integrated into hospice care, but larger studies are needed to confirm its benefits.